Possibly, the stably overexpressed wild-type ABCB1/P-gp might offer cancer cells a mechanism that compensates the effects of a potential mutant ABCB1/P-gp (e.g., F335del) on drug-binding and cytotoxic insults as previously described[20-22,48]. This evidence concerns the gene ABCB1 and cancer.